📣 VC round data is live. Check it out!
- Public Comps
- ALS
ALS Valuation Multiples
Discover ALS's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Charles River, Bangkok Dusit Medical Services, Bio-Techne, Max Healthcare Institute and more.
ALS Overview
About ALS
Founded in the 1880s and listing on the ASX in 1952, ALS operates two divisions: commodities and life sciences. ALS commodities traditionally generated the majority of underlying earnings, providing geochemistry, metallurgy, inspection and mine site services for the global mining industry. Expansion into environmental, pharmaceutical and food testing areas has lessened earnings exposure to commodities.
Founded
1910
HQ

Employees
20.5K
Website
Sectors
Financials (LTM)
EV
$10B
Valuation Multiples
Start free trialALS Financials
ALS reported last 12-month revenue of $2B and EBITDA of $610M.
In the same LTM period, ALS generated $603M in gross profit, $610M in EBITDA, and $282M in net income.
Revenue (LTM)
ALS P&L
In the most recent fiscal year, ALS reported revenue of $2B and EBITDA of $484M.
ALS is profitable as of last fiscal year, with gross margin of 90%, EBITDA margin of 23%, and net margin of 9%.
Financial data powered by Morningstar, Inc.
ALS Stock Performance
ALS has current market cap of $9B, and enterprise value of $10B.
Market Cap Evolution
ALS's stock price is $16.86.
ALS share price decreased by 0.7% in the last 30 days, and increased by 45.1% in the last year.
ALS has an EPS (earnings per share) of $0.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $9B | -1.4% | -0.7% | 13.1% | 45.1% | $0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialALS Valuation Multiples
ALS trades at 4.0x EV/Revenue multiple, and 15.7x EV/EBITDA.
EV / Revenue (LTM)
ALS Financial Valuation Multiples
As of June 3, 2026, ALS has market cap of $9B and EV of $10B.
ALS has a P/E ratio of 30.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ALS Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


ALS Margins & Growth Rates
ALS grew revenue by 11% and EBITDA by 23% in the last fiscal year.
In the most recent fiscal year, ALS reported gross margin of 90%, EBITDA margin of 23%, and net margin of 9%.
ALS Margins
ALS Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
ALS Operational KPIs
ALS's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
ALS's Rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ALS's Rule of X is 49% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
ALS Competitors
ALS competitors include Charles River, Bangkok Dusit Medical Services, Bio-Techne, Max Healthcare Institute, Qiagen, Fortis Healthcare, bioMérieux, Repligen, Sonic Healthcare and Avantor.
Most ALS public comparables operate across Laboratory Services.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | 2.9x | 11.6x | 11.6x | |||
| 2.5x | 2.5x | 10.5x | 10.5x | |||
| 6.5x | 6.5x | 18.5x | 18.4x | |||
| 11.2x | 10.4x | 37.1x | 35.7x | |||
| 4.0x | 4.0x | 11.0x | 10.9x | |||
| 8.0x | 7.8x | 34.3x | 33.7x | |||
| 2.0x | 2.0x | 8.2x | 8.3x | |||
| 9.1x | 8.7x | 37.2x | 44.4x | |||
This data is available for Pro users. Sign up to see all ALS competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by ALS
ALS has acquired 8 companies to date.
Last acquisition by ALS was on March 25th 2024. ALS acquired Wessling Group for undisclosed valuation.
Latest Acquisitions by ALS
| Description | Wessling Group is a Germany-headquartered provider of testing and analysis services in environmental, food, and pharmaceutical sectors. The firm conducts laboratory assessments for contaminants, quality control, and compliance across Europe. With facilities in multiple countries, Wessling Group supports industries like agriculture and healthcare through de.wessling-group.com. | Proanaliz is a Turkish biotechnology laboratory offering testing services for food safety, agriculture, water quality, and swimming pools. The Istanbul-based firm conducts microbiological, chemical, and residue analyses accredited by TS EN ISO 17025. Proanaliz supports exporters with pesticide and heavy metal screenings for EU compliance. Founded in 2012, it processes samples for food producers and municipalities nationwide. | Hrl Holdings is a provider of integrated environmental services combining field sampling, laboratory testing, and cloud-based asset management for water, soil, and air quality monitoring. Operating in Australia, it supports mining, construction, and government projects with accredited labs and mobile data platforms. | MinAnalytical Laboratory Services is an analytical laboratory offering geochemical assays and precious metals testing for mining and exploration. Perth-based in Western Australia, MinAnalytical processes samples using ICP-MS and XRF techniques for gold, copper, and lithium projects. It serves clients in Australia, Africa, and South America with turnaround times under five days. | |
| HQ Country | |||||
| HQ City | Altenberge | Antalya | Brisbane | Sydney | |
| Deal Date | 25 Mar 2024 | 9 Aug 2023 | 6 Sep 2022 | 23 Dec 2021 | |
| Valuation | undisclosed | $3M | $53M | $28M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all ALS acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ALS
| When was ALS founded? | ALS was founded in 1910. |
| Where is ALS headquartered? | ALS is headquartered in Australia. |
| How many employees does ALS have? | As of today, ALS has over 20K employees. |
| Who is the CEO of ALS? | ALS's CEO is Malcolm Deane. |
| Is ALS publicly listed? | Yes, ALS is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of ALS? | ALS trades under ALQ ticker. |
| When did ALS go public? | ALS went public in 1952. |
| Who are competitors of ALS? | ALS main competitors include Charles River, Bangkok Dusit Medical Services, Bio-Techne, Max Healthcare Institute, Qiagen, Fortis Healthcare, bioMérieux, Repligen, Sonic Healthcare, Avantor. |
| What is the current market cap of ALS? | ALS's current market cap is $9B. |
| What is the current revenue of ALS? | ALS's last 12 months revenue is $2B. |
| What is the current revenue growth of ALS? | ALS revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of ALS? | Current revenue multiple of ALS is 4.0x. |
| What is the current EBITDA of ALS? | ALS's last 12 months EBITDA is $610M. |
| What is ALS's EBITDA margin? | ALS's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of ALS? | Current EBITDA multiple of ALS is 15.7x. |
| What is the current FCF of ALS? | ALS's last 12 months FCF is $190M. |
| What is ALS's FCF margin? | ALS's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of ALS? | Current FCF multiple of ALS is 50.4x. |
| How many companies ALS has acquired to date? | As of June 2026, ALS has acquired 8 companies. |
| What was the largest acquisition by ALS? | $53M acquisition of Hrl Holdings on 6th September 2022 was the largest M&A ALS has done to date. |
| In how many companies ALS has invested to date? | ALS hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to ALS
Lists including ALS
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


